Drug Search Results
More Filters [+]

Azelastine

Alternative Names: azelastine, astelin, astepro, optivar, rhinolast
Latest Update: 2024-06-26
Latest Update Note: Clinical Trial Update

Product Description

Azelastine is an antihistamine. It works by preventing the effects of a substance called histamine, which is produced by the body. Histamine can cause itching, sneezing, runny nose, and watery eyes. (Sourced from: https://www.mayoclinic.org/drugs-supplements/azelastine-nasal-route/description/drg-20068252)

Mechanisms of Action: H1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Topical,Nasal

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Rhinitis | Rhinitis, Allergic | Rhinitis, Allergic, Seasonal | Rhinitis, Vasomotor | Rhinitis | Rhinitis, Allergic | Rhinitis, Allergic, Perennial | Rhinitis, Allergic, Seasonal

Known Adverse Events: Dizziness | Headache | Pharyngitis | Epistaxis | Rhinitis | Sinusitis | Sneezing | Dysgeusia | Pain Unspecified | Dermatitis | Dermatitis, Contact | Otitis | Otitis Media

Company: Meda
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Azelastine

Countries in Clinic: Bulgaria, Canada, China, Germany, India, Latvia, Lithuania, Moldova, Poland, Russia

Active Clinical Trial Count: 8

Highest Development Phases

Phase 3: Asthma, Allergic|COVID-19|Conjunctivitis, Allergic|Dust mite Hypersensitivity|Environmental Hypersensitivity|Rhinitis, Allergic|Rhinitis, Allergic, Perennial|Rhinitis, Allergic, Seasonal

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

PM/0059

P3

Not yet recruiting

Conjunctivitis, Allergic|Environmental Hypersensitivity|Dust mite Hypersensitivity|Rhinitis, Allergic|Asthma, Allergic

2026-08-31

AZEL-NS-2001

P2

Completed

Rhinitis, Allergic, Seasonal

2024-02-23

35%

2021-006485-20

P3

Active, not recruiting

COVID-19

2023-08-22

CLK21001/SAN-0677

P3

Completed

Rhinitis, Allergic, Seasonal

2023-06-20

66%

CLK21001/SAN-0677

P3

Completed

Rhinitis, Allergic, Seasonal

2023-06-20

66%

Recent News Events